{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 459985202
| IUPAC_name = 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione
| image = Budesonid Grundstruktur V4.svg
| width = 250
| image2 = Budesonide ball-and-stick.png
| width2 = 250

<!--Clinical data-->
| tradename = Pulmicort, Rhinocort, others
| Drugs.com = {{drugs.com|monograph|budesonide}}
| MedlinePlus = a608007
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = S2
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = OTC
| legal_US_comment = and Rx-only
| routes_of_administration = By mouth, nasal, tracheal, rectal

<!--Pharmacokinetic data-->
| bioavailability = 10-20% (first pass effect)
| protein_bound = 85-90%
| metabolism = Hepatic [[CYP3A4]]
| elimination_half-life = 2.0-3.6 hours
| excretion = [[Urine]], [[feces]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51333-22-3
| ATC_prefix = A07
| ATC_suffix = EA06
| ATC_supplemental =  {{ATC|D07|AC09}}, {{ATC|R01|AD05}}, {{ATC|R03|BA02}}
| PubChem = 40000
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01222
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4444479
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q3OKS62Q6X
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00246
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1370
| PDB_ligand = 8W5

<!--Chemical data-->
| C=25 | H=34 | O=6
| molecular_weight = 430.534 g/mol
| SMILES = CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VOVIALXJUBGFJZ-KWVAZRHASA
| synonyms = 11β,21-Dihydroxy-16α,17α-(butylidenebis(oxy))pregna-1,4-diene-3,20-dione
}}

<!-- Definition and medical uses -->
'''Budesonide''' ('''BUD'''), sold under the brand name '''Pulmicort''' among others, is a medication of the [[corticosteroid]] type.<ref name=AHFS2015/> It is available as an [[metered-dose inhaler|inhaler]], pill, [[nasal spray]], and rectal forms.<ref name=AHFS2015>{{cite web|title=Budesonide|url=http://www.drugs.com/monograph/budesonide.html|publisher=The American Society of Health-System Pharmacists|accessdate=Dec 2, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151128150235/http://www.drugs.com/monograph/budesonide.html|archivedate=2015-11-28|df=}}</ref><ref name=AHFS2015ENT>{{cite web|title=Budesonide eent|url=http://www.drugs.com/monograph/budesonide-eent.html|publisher=The American Society of Health-System Pharmacists|accessdate=Dec 2, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151208195318/http://www.drugs.com/monograph/budesonide-eent.html|archivedate=2015-12-08|df=}}</ref> The inhaled form is used in the long-term management of [[asthma]] and [[chronic obstructive pulmonary disease]] (COPD).<ref name=AHFS2015 /><ref>{{cite journal|last1=De Coster|first1=DA|last2=Jones|first2=M|title=Tailoring of corticosteroids in COPD management.|journal=Current respiratory care reports|date=2014|volume=3|pages=121–132|pmid=25089228|doi=10.1007/s13665-014-0084-2|pmc=4113685}}</ref><ref>{{cite journal|last1=Christophi|first1=GP|last2=Rengarajan|first2=A|last3=Ciorba|first3=MA|title=Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach.|journal=Clinical and experimental gastroenterology|date=2016|volume=9|pages=125–30|pmid=27274301|doi=10.2147/CEG.S80237|pmc=4876845}}</ref> The nasal spray is used for [[allergic rhinitis]] and [[nasal polyp]]s.<ref name=AHFS2015ENT/><ref>{{cite journal|last1=Rudmik|first1=L|last2=Schlosser|first2=RJ|last3=Smith|first3=TL|last4=Soler|first4=ZM|title=Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis.|journal=The Laryngoscope|date=July 2012|volume=122|issue=7|pages=1431–7|pmid=22410935|doi=10.1002/lary.23259}}</ref> The pills in a delayed release form and rectal forms may be used for [[inflammatory bowel disease]] including [[Crohn's disease]], [[ulcerative colitis]] and [[microscopic colitis]].<ref name=Sil2011>{{cite journal|vauthors=Silverman J, Otley A | title=Budesonide in the treatment of inflammatory bowel disease. | journal=Expert Rev Clin Immunol | year= 2011 | volume= 7 | issue= 4 | pages= 419–28 | pmid=21790284 | doi=10.1586/eci.11.34 | pmc= }}</ref><ref>{{cite journal |vauthors=Pardi DS, Tremaine WJ, Carrasco-Labra A |title=American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis |journal=Gastroenterology |volume=150 |issue=1 |pages=247–274.e11 |year=2016 |pmid=26584602 |doi=10.1053/j.gastro.2015.11.006 |url=}}</ref>

<!-- Side effects and mechanism -->
Common side effects with the inhaled form include respiratory infections, cough, and headaches.<ref name=AHFS2015/> Common side effects with the pills include feeling tired, vomiting, and joint pains.<ref name=AHFS2015/> Serious side effects include an increased risk of infection, loss of bone strength, and [[cataracts]].<ref name=AHFS2015/> Long-term use of the pill form may cause [[adrenal insufficiency]].<ref name=AHFS2015/> Stopping the pills suddenly following long-term use may therefore be dangerous.<ref name=AHFS2015/> The inhaled form is generally safe in [[pregnancy]].<ref name=AHFS2015/> Budesonide is mainly acting as a [[glucocorticoid]].<ref name=AHFS2015/>

<!-- Society and culture -->
Budesonide was initially patented in 1973.<ref>{{cite book|last1=Domeij|first1=Bengt|title=Pharmaceutical patents in Europe|date=2000|publisher=Kluwer Law International|location=The Hague|isbn=9789041113481|page=278|url=https://books.google.ca/books?id=KZfvZN2WfjcC&pg=PA278|deadurl=no|archiveurl=https://web.archive.org/web/20151208072850/https://books.google.ca/books?id=KZfvZN2WfjcC&pg=PA278|archivedate=2015-12-08|df=}}</ref> Commercial use as an asthma medication began in 1981.<ref>{{cite book|last1=Hamley|first1=Peter|title=Small Molecule Medicinal Chemistry: Strategies and Technologies|date=2015|publisher=John Wiley & Sons|isbn=9781118771693|page=390|url=https://books.google.ca/books?id=LOudCgAAQBAJ&pg=PA390|deadurl=no|archiveurl=https://web.archive.org/web/20151208062120/https://books.google.ca/books?id=LOudCgAAQBAJ&pg=PA390|archivedate=2015-12-08|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> Some forms are available as a [[generic medication]].<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=451}}</ref> The wholesale price in the [[developing world]] for an inhaler containing 200 doses is about 5 to 7 USD as of 2014.<ref>{{cite web|title=Budesonide|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=BUD200I&s_year=2014&year=2014&str=200%20mcg%2Fdose&desc=Budesonide&pack=new&frm=INHALER&rte=PO&class_code2=28%2E&supplement=&class_name=%28%29%3Cbr%3E%2828%2E%29Ear%2C%20nose%20and%20throat%20medicines%20in%20children%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=5 December 2015}}</ref> As of 2015 the cost for a typical month of medication in the United States is 100 to 200 USD.<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=451}}</ref>

==Medical uses==

===Asthma===
Budesonide is [[nebulize]]d for maintenance and prophylactic treatment of [[asthma]] including patients who require oral [[corticosteroids]] and those who may benefit from a systemic dose reduction.<ref>Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011. Available at http://www.ginasthma.org {{webarchive|url=https://web.archive.org/web/20131014032230/http://www.ginasthma.org/ |date=2013-10-14 }}</ref>

===Inflammatory bowel disease===
Formulations of delayed-release Budesonide are an effective treatment for mild-to-moderately active [[Crohn's disease]] involving the [[ileum]] and/or ascending colon.<ref>{{cite journal | vauthors = Lichtenstein GR, Hanauer SB, Sandborn WJ | year = 2009 | title = Management of Crohn's Disease in Adults | url = | journal = Am J Gastroenterol | volume = 104 | issue = 2| pages = 465–83 | pmid = 19174807 | doi=10.1038/ajg.2008.168}}</ref>  A Cochrane review found evidence for up to 3 months (but not longer) of maintenance of remission Crohn's disease.<ref name="pmid25141071">{{cite journal | vauthors=Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, etal | title=Budesonide for maintenance of remission in Crohn's disease. | journal=Cochrane Database Syst Rev | year=2014 | volume=8 | issue= | pages=CD002913 | pmid=25141071 | doi=10.1002/14651858.CD002913.pub3 | pmc= | url=http://www.ncbi.nlm.nih.gov/pubmed/25141071 | deadurl=no | archiveurl=https://web.archive.org/web/20150731123459/http://www.ncbi.nlm.nih.gov/pubmed/25141071 | archivedate=2015-07-31 | df= }}</ref>

Budesonide assists in the induction of remission in people with active [[ulcerative colitis]].<ref>{{cite journal | author = Habal FM, Huang VW | year = 2012 | title = Review Article: A Decision-Making Algorithm For the Management of Pregnancy in the Inflammatory Bowel Disease Patient | url = | journal = Aliment Pharmacol Ther | volume = 35 | issue = 5| pages = 501–15 | pmid = 22221203 | doi=10.1111/j.1365-2036.2011.04967.x}}</ref>

Budesonide is highly effective and recommended as the drug of choice in [[microscopic colitis]], for induction and maintenance of remission, and for both the [[lymphocytic colitis]] and [[collagenous colitis]] forms.<ref>{{Cite web|url=http://www.gastrojournal.org/article/S0016-5085(15)01623-6/pdf|title=American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis|last=Pardi|first=Darrell|date=2016|website=www.gastrojournal.org|access-date=}}</ref>

===Allergic rhinitis===
Nasal spray budesonide is a treatment for [[allergic rhinitis]].<ref>{{cite journal|last1=Stanaland|first1=BE|title=Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review.|journal=Clinical therapeutics|date=April 2004|volume=26|issue=4|pages=473–92|pmid=15189745|doi=10.1016/s0149-2918(04)90050-1}}</ref>

==Side effects==
Budesonide may cause:<ref name="emedicinehealth">[http://www.emedicinehealth.com/budesonide-nasal_aerosol_inhaler/article.htm BUDESONIDE - NASAL AEROSOL INHALER (Rhinocort) side effects, medical uses, and drug interactions<!-- Bot generated title -->] {{webarchive |url=https://web.archive.org/web/20081106080137/http://www.emedicinehealth.com/budesonide-nasal_aerosol_inhaler/article.htm |date=November 6, 2008 }}</ref>

* Nose irritation or burning 
* Bleeding or sores in the nose 
* Lightheadedness 
* Upset stomach 
* Cough 
* Hoarseness 
* Dry mouth
* Rash
* Sore throat
* [[Bad taste in mouth]]
* Change in [[mucus]]
* Blurred vision <ref>{{cite web|title=Budesonide: CMDh scientific conclusions and grounds for variation, amendments to the product information and timetable for the implementation - PSUSA/00000449/201604|url=http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223322.pdf|publisher=European Medicines Agency (EMA)|accessdate=19 May 2017|format=pdf|date=March 10, 2017|deadurl=no|archiveurl=https://web.archive.org/web/20170908174615/http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2017/03/WC500223322.pdf|archivedate=8 September 2017|df=}}</ref>

In addition, the following symptoms should be reported immediately: 

* Difficulty breathing or swelling of the face 
* White patches in the throat, mouth, or nose 
* Irregular menstrual periods 
* Severe acne
* On rare occasions, behavioral changes (mostly affecting children)<ref name="emedicinehealth" />

==Contraindications==
Budesonide is contraindicated as a primary treatment of [[status asthmaticus]] or other acute episode of asthma where intensive measures are required.<ref>{{cite journal | vauthors=Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT, McCance DR  | year = 2002 | title = Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate | url = | journal = Eur Respir J | volume = 19 | issue = 6| pages = 1207–9 | pmid = 12108877 | doi=10.1183/09031936.02.00274402}}</ref>  It is also contraindicated for patients who have hypersensitivity to budesonide.<ref>{{cite journal |vauthors=Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D | year = 2002 | title = Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom | url = | journal = Arch Dis Child | volume = 87 | issue = 6| pages = 457–61 | pmid = 12456538 | pmc=1755820 | doi=10.1136/adc.87.6.457}}</ref>

==Interactions==
Those taking tablets or capsules orally should avoid grapefruit juice and [[echinacea]].

* Grapefruit juice may double [[bioavailability]] of oral budesonide.
* Echinacea diminishes [[bioavailability]].

Also, high fat meals delay absorption but do not impede absorption.

==Pharmacology==
Budesonide is an agonist of glucocorticoid receptors. Among its effects are:

* Controls the rate of protein synthesis.
* Depresses the migration of polymorphonuclear leukocytes and fibroblasts.
* Reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.
* Has a potent glucocorticoid activity and weak mineralocorticoid activity.

==Pharmacokinetics==
* Onset of action: Nebulization: 2–8 days; Inhalation: 24 hours
* Peak effect: Nebulization: 4–6 weeks; Inhalation: 1–2 weeks
* Distribution: 2.2-3.9 L/kg
* Protein binding: 85% to 90%
* Metabolism: Hepatic via CYP3A4 to two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide; minor activity
* Bioavailability: Limited by high first-pass effect; Capsule: 9% to 21%; Nebulization: 6%; Inhalation: 6% to 13%
* Half-life elimination: 2-3.6 hours
* Time to peak: Capsule: 0.5–10 hours (variable in Crohn's disease); Nebulization: 10–30 minutes; Inhalation: 1–2 hours; Tablet: 7.4-19.2 hours
* Excretion: Urine (60%) and feces as metabolites.

==Chemistry==
{{See also|List of corticosteroids|List of corticosteroid cyclic ketals}}

Budesonide, also known as 11β,21-dihydroxy-16α,17α-(butylidenebis(oxy))pregna-1,4-diene-3,20-dione, is a [[synthetic compound|synthetic]] [[pregnane]] [[steroid]] and non-[[halogen]]ated [[corticosteroid cyclic ketal|cyclic ketal]] [[corticosteroid]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA186|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=186,1011|deadurl=no|archiveurl=https://web.archive.org/web/20170908174614/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA186|archivedate=8 September 2017|df=}}</ref><ref name="LemkeWilliams2008">{{cite book|author1=Thomas L. Lemke|author2=David A. Williams|title=Foye's Principles of Medicinal Chemistry|url=https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1253|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6879-5|pages=1253–|deadurl=no|archiveurl=https://web.archive.org/web/20170908174614/https://books.google.com/books?id=R0W1ErpsQpkC&pg=PA1253|archivedate=2017-09-08|df=}}</ref> It is the C16α [[hydroxyl group|hydroxyl]], C16α,17α cyclic ketal with [[butyraldehyde]] [[chemical derivative|derivative]] of [[prednisolone]] (11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione).<ref name="Elks2014" /><ref name="LemkeWilliams2008" />

===Stereoisomerism===
{| class="wikitable" style="text-align:center"
|- class="hintergrundfarbe6"
! colspan="2"| Budesonide<br /><small>(2 stereoisomers)</small>
|-
| [[File:22R-Budesonid V4.svg|220px|''(R)''-Budesonid]]<br /><small>(22''R'')-configuration</small>
| [[File:22S-Budesonid V4.svg|220px|''(S)''-Budesonid]]<br /><small>(22''S'')-configuration</small>
|}

==Society and culture==

===Brand names===
[[File:Budesonide and formoterol inhaler.jpg|thumb|200px|Inhaler for a powder based in budesonide and [[formoterol]]]]

Aeronide (TH); Aquacort (DE); B Cort (CO); Bronex (PH); Budair (MY); Budecort DP (MY); Budenofalk (DE, GB, HK, KP, PH, SG); Budeson (AR); Budeson Aqua (AR); BudeSpray (TH); Budiair (KP); Budicort Respules (IL); Bunase (TH); Clebudan (CN); Cycortide (HK); Denecort (PH); Duasma (TW); Eltair (MY); Entocort (AR, AT, BE, BR, CH, CZ, DK, FI, FR, GB, HK, IE, IL, IT, KP, NL, NO, PL, PT, SE, TR); Giona Easyhaler (MY, SG, TH); Inflammide (PE); Miflonid (CZ); Miflonide (BE, DE, IL, IT, NZ, PT); Neumocort (PY); Novopulmon (DE, FR); Pulmicon Susp for Nebulizer (KP); Pulmicort (AT, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GB, GR, GT, HN, ID, IN, NI, NL, NO, PA, PK, PL, PT, RU, SE, SV, TR, TW, UY, VE, ZA); Pulmicort Nasal Turbohaler (CL, KE, MU, NG); Pulmicort Turbuhaler (KE, MU, NG); Rafton (FR); Rhinocort (AU); Rhinocort Aqua (HK); Rhinoside (GR); Symbicort (FR, US, ZA) Uceris (US)

==See also==
* [[Azelastine]]
* [[Fluticasone propionate]]

==References==
{{Reflist}}

==External links==
* [https://web.archive.org/web/20100216094309/http://www.entocortec.com/PDF/ENTOCORT_PI.pdf Entocort EC Prescribing information] Prometheus Laboratories (PDF)
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a608007.html Budesonide Oral (Entocort EC)] [[MedlinePlus]], [[National Institutes of Health]] (NIH), [[United States National Library of Medicine|U.S. National Library of Medicine]]
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601030.html Budesonide Nasal Spray (Rhinocort)] [[MedlinePlus]], [[National Institutes of Health]] (NIH), [[United States National Library of Medicine|U.S. National Library of Medicine]]
* [http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601030.html Budesonide Oral Inhalation (Symbicort)] [[MedlinePlus]], [[National Institutes of Health]] (NIH), [[United States National Library of Medicine|U.S. National Library of Medicine]]

{{Glucocorticoids}}
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}}
{{Nasal preparations}}
{{Asthma_and_copd_rx}}
{{Glucocorticoidics}}
{{AstraZeneca}}

[[Category:Antiasthmatic drugs]]
[[Category:AstraZeneca]]
[[Category:Corticosteroid cyclic ketals]]
[[Category:Corticosteroids]]
[[Category:Cyclic acetals with aldehydes]]
[[Category:Diketones]]
[[Category:Diols]]
[[Category:Glucocorticoids]]
[[Category:Pregnanes]]
[[Category:RTT]]